search
Back to results

Shockwave Coronary Lithoplasty Study

Primary Purpose

Coronary Stenosis

Status
Completed
Phase
Not Applicable
Locations
Australia
Study Type
Interventional
Intervention
Shockwave Coronary Lithoplasty System
Sponsored by
Shockwave Medical, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Stenosis focused on measuring coronary artery disease, calcified lesions, lithotripsy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. At least 18 years of age and able to give informed consent.
  2. Patients in Sinus Rhythm.
  3. Patients with significant (> 50% diameter stenosis) native coronary artery disease including stable or unstable angina and silent ischemia, suitable for PCI.
  4. Ability to tolerate dual antiplatelet agent (i.e. aspirin, clopidogrel or prasugrel). For 1 year and single therapy for life.
  5. Patient is able and willing to comply with all assessments in the study.
  6. Stenosis of LAD, RCA or LCX artery ≥50% in a reference vessel of 2.5mm-3.5 mm diameter and ≤ 22 mm length, as assessed by two orthogonal angiographic views.
  7. Calcification with parallel calcium at least 50% the length of the lesion.
  8. At the time of the procedure the subject is in Sinus Rhythm.
  9. Single lesions per vessel.
  10. Ability to pass a 0.014" guide wire across the lesion.

Exclusion Criteria:

  1. Concomitant use of Rotablator, Cutting Balloon, or investigational coronary devices.
  2. Additional planned coronary interventions for a non-target lesion within 180 days of the study procedure.
  3. Left ventricular ejection fraction < 40%
  4. Patients refusing or not candidates for emergency coronary artery bypass grafting (CABG) surgery
  5. Uncontrolled severe hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg)
  6. Patients who are not candidates for dual anti-platelet therapy for 30 days and chronic single anti-platelet therapy
  7. Severe renal failure with creatinine >2.5 mg/dL
  8. Untreated pre-procedural hemoglobin <10 g/dL
  9. Coagulopathy manifested by platelet count <100,000 or International Normalized ratio (INR) >1.7 (INR is only required in patients who have taken warfarin within 2 weeks of enrollment)
  10. Patients in cardiogenic shock
  11. Acute myocardial infarction (MI) within the past one (1) month, and/or elevated CPK (and abnormal Troponin-I) at the time of enrollment
  12. Patients with a life expectancy of less than 1 year
  13. Target main branch vessel < 2.5 mm in diameter
  14. Target main branch lesion > 22 mm in length
  15. Chronic Total Occlusion (CTO).
  16. Previous stent procedure within 10 mm of target lesion
  17. Prior PCI procedure within the last 6 months.
  18. Target lesion demonstrating severe dissection prior to planned use of the Shockwave device
  19. Unprotected Left Main diameter stenosis ≥ 50%
  20. Visible thrombus (by angiography) at target lesion site
  21. Patient has active systemic infection
  22. Patient with an externally-connected intracardiac catheter or pacemaker.
  23. Patient with an implantable pacemaker or defibrillator.
  24. Patient has connective tissue disease (e.g., Marfan's syndrome)
  25. Patient has a hypercoagulable disorder.
  26. Patient has allergy to imaging contrast media for which they cannot be pre-medicated.
  27. Evidence of aneurysm or acute thrombus in target vessel.
  28. Patients with prior sternotomy as a result of thoracic surgery

Sites / Locations

  • St. Vincent's Hospital Melbourne

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Shockwave Coronary Lithoplasty System

Arm Description

Patients receive Lithoplasty treatment prior to placement of coronary stent. IVUS or OCT documents patency pre and post Lithoplasty. Patient is followed for patency at discharge, 30 days and 6 months following treatment.

Outcomes

Primary Outcome Measures

Safety - Acute, as indicated by number of subjects that do not experience death following delivery of shockwave energy
Safety - Acute, as indicated by number of subjects that do not experience tamponade following delivery of shockwave energy
Safety - Acute, as indicated by number of subjects that do not experience dissection, occlusion or perforation of the coronary artery that requires additional intervention to treat besides stenting following delivery of shockwave energy
Safety - Acute, as indicated by number of subjects that do not experience aneurysm following delivery of shockwave energy
Safety - Acute, as indicated by number of subjects that do not experience MI (CPK > 5 x uln) following delivery of shockwave energy
Safety - Acute, as indicated by number of subjects that do not experience cardiogenic shock following delivery of shockwave energy
Safety - Acute, as indicated by number of subjects that do not experience distal embolization compromising blood flow, and requiring intervention following delivery of shockwave energy
Safety - Acute, as indicated by number of subjects that do not experience blood transfusion due to excessive blood loss following delivery of shockwave energy
Safety - Acute, as indicated by number of subjects that do not experience stroke following delivery of shockwave energy
Safety - 30 days (Number of subjects without any procedure and/or device related adverse events)
Safety - 30 days (Number of subjects without target lesion revascularization (TLR)
Safety - 30 days (Number of subjects without groin complications)
Safety - 180 days (Number of subjects without any procedure and/or device related adverse events)
Safety - 180 days (Number of subjects without any target lesion revascularization (TLR))
Performance - Acute technical success of the device
Successful delivery of the device and administration of lithotripsy-enhanced low pressure balloon dilation to the target lesion Residual stenosis of ≤50% of the reference vessel size of the target lesion assessed by angiography and either IVUS or OCT. Successful access of the treatment site with a coronary stent
Safety - Acute, as indicated by number of subjects that do not experience ventricular arrhythmic event requiring intervention to re-establish normal rhythm following delivery of shockwave energy

Secondary Outcome Measures

Full Information

First Posted
January 16, 2015
Last Updated
July 19, 2017
Sponsor
Shockwave Medical, Inc.
Collaborators
Yale Cardiovascular Research Group, Massachusetts General Hospital, Pacific Clinical Research Group
search

1. Study Identification

Unique Protocol Identification Number
NCT02758379
Brief Title
Shockwave Coronary Lithoplasty Study
Official Title
Early Safety and Feasibility Study of the Shockwave Coronary Lithoplasty™ System in Coronary Arteries
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
July 2014 (undefined)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
March 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shockwave Medical, Inc.
Collaborators
Yale Cardiovascular Research Group, Massachusetts General Hospital, Pacific Clinical Research Group

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this clinical trial is to study the early safety and feasibility of the Shockwave Coronary Lithoplasty System. To demonstrate that the Shockwave device can safely and effectively deliver localized shockwave energy for balloon dilatation of calcified, stenotic, de novo coronary lesions.
Detailed Description
Prospective, non-randomized, single center First In Human (FIH) trial for treatment of stenotic calcified coronary lesions with the Shockwave Lithoplasty System. Patients will be enrolled and consented in the study based on history and in some instances an angiogram obtained prior to the study. The study is designed to demonstrate that the Shockwave device can safely and effectively deliver localized shockwave energy for balloon dilatation of calcified, stenotic, coronary arteries. Subjects will be prepared for PCI per the institution's standard protocol. Medications will be administered per the treatment protocol. Femoral access will be obtained using a 6F access sheath, and guiding catheter placed at the ostia of the right or left coronary artery. Baseline angiography of the culprit lesion will be performed prior to placement of a 0.014" guide wire. Baseline and either IVUS or OCT will be performed to determine the Maximum Lumen Area (MLA), percent stenosis, and volumetric lesion assessment. Baseline angiography will be performed to determine lesion length, % stenosis and reference vessel diameter. The investigational device will be prepped per the IFU and positioned at the target lesion. The distal end of the balloon catheter will be connected to the patient cable. The balloon catheter will be inflated to 4 atm and the investigator will deliver 10 pulses for 20 seconds. The balloon will then be inflated to reference vessel diameter and then deflated to reestablish flow and complete one treatment cycle. The treatment cycle will then be repeated. Angiography and either IVUS or OCT will be repeated for the treated lesion.. A coronary stent will be deployed at the site of treatment. Angiography and either IVUS or OCT will be performed following stent placement. Patients will be followed through discharge and at 30 and 180 days. A subset of up to five (5) subjects will receive an angiographic assessment at the 180 day follow up visit, per the Sponsor's discretion.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Stenosis
Keywords
coronary artery disease, calcified lesions, lithotripsy

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Shockwave Coronary Lithoplasty System
Arm Type
Experimental
Arm Description
Patients receive Lithoplasty treatment prior to placement of coronary stent. IVUS or OCT documents patency pre and post Lithoplasty. Patient is followed for patency at discharge, 30 days and 6 months following treatment.
Intervention Type
Device
Intervention Name(s)
Shockwave Coronary Lithoplasty System
Intervention Description
Lithotripsy shockwaves are used to fracture calcified lesions in the coronary arteries
Primary Outcome Measure Information:
Title
Safety - Acute, as indicated by number of subjects that do not experience death following delivery of shockwave energy
Time Frame
Post-procedure (within 24 hours following procedure)
Title
Safety - Acute, as indicated by number of subjects that do not experience tamponade following delivery of shockwave energy
Time Frame
Post-procedure (within 24 hours following procedure)
Title
Safety - Acute, as indicated by number of subjects that do not experience dissection, occlusion or perforation of the coronary artery that requires additional intervention to treat besides stenting following delivery of shockwave energy
Time Frame
Post-procedure (within 24 hours following procedure)
Title
Safety - Acute, as indicated by number of subjects that do not experience aneurysm following delivery of shockwave energy
Time Frame
Post-procedure (within 24 hours following procedure)
Title
Safety - Acute, as indicated by number of subjects that do not experience MI (CPK > 5 x uln) following delivery of shockwave energy
Time Frame
Post-procedure (within 24 hours following procedure)
Title
Safety - Acute, as indicated by number of subjects that do not experience cardiogenic shock following delivery of shockwave energy
Time Frame
Post-procedure (within 24 hours following procedure)
Title
Safety - Acute, as indicated by number of subjects that do not experience distal embolization compromising blood flow, and requiring intervention following delivery of shockwave energy
Time Frame
Post-procedure (within 24 hours following procedure)
Title
Safety - Acute, as indicated by number of subjects that do not experience blood transfusion due to excessive blood loss following delivery of shockwave energy
Time Frame
Post-procedure (within 24 hours following procedure)
Title
Safety - Acute, as indicated by number of subjects that do not experience stroke following delivery of shockwave energy
Time Frame
Post-procedure (within 24 hours following procedure)
Title
Safety - 30 days (Number of subjects without any procedure and/or device related adverse events)
Time Frame
30 days post procedure
Title
Safety - 30 days (Number of subjects without target lesion revascularization (TLR)
Time Frame
30 days post procedure
Title
Safety - 30 days (Number of subjects without groin complications)
Time Frame
30 days post procedure
Title
Safety - 180 days (Number of subjects without any procedure and/or device related adverse events)
Time Frame
180 days post procedure
Title
Safety - 180 days (Number of subjects without any target lesion revascularization (TLR))
Time Frame
180 days post procedure
Title
Performance - Acute technical success of the device
Description
Successful delivery of the device and administration of lithotripsy-enhanced low pressure balloon dilation to the target lesion Residual stenosis of ≤50% of the reference vessel size of the target lesion assessed by angiography and either IVUS or OCT. Successful access of the treatment site with a coronary stent
Time Frame
Post-procedure (within 24 hours following procedure)
Title
Safety - Acute, as indicated by number of subjects that do not experience ventricular arrhythmic event requiring intervention to re-establish normal rhythm following delivery of shockwave energy
Time Frame
Post-procedure (within 24 hours following procedure)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: At least 18 years of age and able to give informed consent. Patients in Sinus Rhythm. Patients with significant (> 50% diameter stenosis) native coronary artery disease including stable or unstable angina and silent ischemia, suitable for PCI. Ability to tolerate dual antiplatelet agent (i.e. aspirin, clopidogrel or prasugrel). For 1 year and single therapy for life. Patient is able and willing to comply with all assessments in the study. Stenosis of LAD, RCA or LCX artery ≥50% in a reference vessel of 2.5mm-3.5 mm diameter and ≤ 22 mm length, as assessed by two orthogonal angiographic views. Calcification with parallel calcium at least 50% the length of the lesion. At the time of the procedure the subject is in Sinus Rhythm. Single lesions per vessel. Ability to pass a 0.014" guide wire across the lesion. Exclusion Criteria: Concomitant use of Rotablator, Cutting Balloon, or investigational coronary devices. Additional planned coronary interventions for a non-target lesion within 180 days of the study procedure. Left ventricular ejection fraction < 40% Patients refusing or not candidates for emergency coronary artery bypass grafting (CABG) surgery Uncontrolled severe hypertension (systolic BP >180 mm Hg or diastolic BP >110 mm Hg) Patients who are not candidates for dual anti-platelet therapy for 30 days and chronic single anti-platelet therapy Severe renal failure with creatinine >2.5 mg/dL Untreated pre-procedural hemoglobin <10 g/dL Coagulopathy manifested by platelet count <100,000 or International Normalized ratio (INR) >1.7 (INR is only required in patients who have taken warfarin within 2 weeks of enrollment) Patients in cardiogenic shock Acute myocardial infarction (MI) within the past one (1) month, and/or elevated CPK (and abnormal Troponin-I) at the time of enrollment Patients with a life expectancy of less than 1 year Target main branch vessel < 2.5 mm in diameter Target main branch lesion > 22 mm in length Chronic Total Occlusion (CTO). Previous stent procedure within 10 mm of target lesion Prior PCI procedure within the last 6 months. Target lesion demonstrating severe dissection prior to planned use of the Shockwave device Unprotected Left Main diameter stenosis ≥ 50% Visible thrombus (by angiography) at target lesion site Patient has active systemic infection Patient with an externally-connected intracardiac catheter or pacemaker. Patient with an implantable pacemaker or defibrillator. Patient has connective tissue disease (e.g., Marfan's syndrome) Patient has a hypercoagulable disorder. Patient has allergy to imaging contrast media for which they cannot be pre-medicated. Evidence of aneurysm or acute thrombus in target vessel. Patients with prior sternotomy as a result of thoracic surgery
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Whitbourn, M.D.
Organizational Affiliation
St. Vincent Hospital, Melbourne, Australia
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Vincent's Hospital Melbourne
City
Melbourne
State/Province
Victoria
Country
Australia

12. IPD Sharing Statement

Learn more about this trial

Shockwave Coronary Lithoplasty Study

We'll reach out to this number within 24 hrs